论文部分内容阅读
目的探析抗病毒治疗对行根治切除术肝癌合并乙型肝炎(乙肝)病毒(HBV)感染患者的应用效果。方法 80例行根治切除术的肝癌合并HBV感染患者,按照乙型肝炎病毒脱氧核糖核酸(HBV-DNA)水平及是否接受抗病毒治疗分为四组,甲组HBV-DNA<105 copies/ml,接受抗病毒治疗;乙组HBV-DNA<105 copies/ml,未接受抗病毒治疗;丙组HBV-DNA≥105 copies/ml,接受抗病毒治疗;丁组HBV-DNA≥105 copies/ml,未接受抗病毒治疗;每组20例。对各组患者的HBV-DNA水平、肝功能指标水平及并发症发生情况予以统计对比。结果甲组患者HBV-DNA水平为(0.8±0.3)log copies/ml,明显低于乙组患者的(2.6±0.7)log copies/ml,差异具有统计学意义(P<0.05)。丙组患者HBV-DNA水平为(4.1±0.9)log copies/ml,明显低于丁组患者的(6.9±0.8)log copies/ml,差异具有统计学意义(P<0.05)。甲组患者谷丙转氨酶(ALT)水平为(71.5±20.3)U/L,血清白蛋白(ALB)水平为(39.6±4.5)g/L,前白蛋白(PA)水平为(209.5±61.5)mg/L,与乙组患者的(112.5±22.2)U/L、(36.2±4.7)g/L、(174.2±58.3)mg/L相比,差异均具有统计学意义(P<0.05)。丙组患者ALT水平为(97.9±18.1)U/L,ALB水平为(39.0±4.5)g/L,PA水平为(198.5±51.2)mg/L,与丁组患者的(151.5±23.6)U/L、(35.4±4.2)g/L、(153.5±48.8)mg/L相比,差异均具有统计学意义(P<0.05)。甲组并发症发生率为5.0%,低于乙组的30.0%,差异具有统计学意义(P<0.05)。丙组并发症发生率为10.0%,低于丁组的40.0%,差异具有统计学意义(P<0.05)。结论对行根治切除术肝癌合并HBV感染患者给予抗病毒治疗的临床效果更佳,可明显改善患者肝功能,降低患者HBV-DNA水平,减少并发症的发生,是一种值得临床应用的治疗方法。
Objective To investigate the effect of antiviral therapy on radical hepatocellular carcinoma patients with hepatitis B virus (HBV) infection. Methods Eighty patients with hepatocellular carcinoma who underwent radical resection combined with HBV infection were divided into four groups according to the level of HBV-DNA and whether antiviral therapy was given. The HBV-DNA of group A was less than 105 copies / ml, Group B HBV-DNA <105 copies / ml, did not receive antiviral therapy; Group C HBV-DNA≥105 copies / ml, receiving antiviral therapy; Antiviral therapy; 20 cases in each group. The levels of HBV-DNA, the level of liver function and the incidence of complications in each group were statistically compared. Results The level of HBV DNA in group A was (0.8 ± 0.3) log copies / ml, which was significantly lower than that in group B (2.6 ± 0.7) log copies / ml. The difference was statistically significant (P <0.05). The HBV-DNA level in group C was (4.1 ± 0.9) log copies / ml, which was significantly lower than that in group (6.9 ± 0.8) log copies / ml. The difference was statistically significant (P <0.05). The ALT level in group A was (71.5 ± 20.3) U / L, the level of serum albumin (ALB) was (39.6 ± 4.5) g / L and the level of prealbumin was (209.5 ± 61.5) (P <0.05) compared with those in group B (112.5 ± 22.2) U / L, (36.2 ± 4.7) g / L and (174.2 ± 58.3) mg / L respectively. The level of ALT in group C was (97.9 ± 18.1) U / L, ALB was (39.0 ± 4.5) g / L, PA was (198.5 ± 51.2) mg / L in group C, (35.4 ± 4.2) g / L, (153.5 ± 48.8) mg / L, the differences were statistically significant (P <0.05). The incidence of complications in group A was 5.0%, which was lower than that in group B (30.0%), the difference was statistically significant (P <0.05). The complication rate in group C was 10.0%, which was lower than that in group 40.0%. The difference was statistically significant (P <0.05). Conclusions The curative effect of antiviral therapy on patients with hepatocellular carcinoma complicated with HBV infection after radical resection is better, which can significantly improve the liver function, reduce the level of HBV-DNA in patients and reduce the incidence of complications. It is a worthy clinical treatment .